[go: up one dir, main page]

WO2006079999A3 - Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist - Google Patents

Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist Download PDF

Info

Publication number
WO2006079999A3
WO2006079999A3 PCT/IB2006/051080 IB2006051080W WO2006079999A3 WO 2006079999 A3 WO2006079999 A3 WO 2006079999A3 IB 2006051080 W IB2006051080 W IB 2006051080W WO 2006079999 A3 WO2006079999 A3 WO 2006079999A3
Authority
WO
WIPO (PCT)
Prior art keywords
mind
induction
nmda antagonist
ht2a agonist
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/051080
Other languages
French (fr)
Other versions
WO2006079999A2 (en
Inventor
Frederik H Barth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IB2006/051080 priority Critical patent/WO2006079999A2/en
Publication of WO2006079999A2 publication Critical patent/WO2006079999A2/en
Publication of WO2006079999A3 publication Critical patent/WO2006079999A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It has been discovered that the administration of a hallucinogenic 5-HT2A agonist in combination with a NMDA antagonist to a human being induces a novel and particular state of the human mind. This state of mind is non-psychotic and benign. The induction of this novel and particular state of the human mind can be used for therapeutic, recreational and other useful purposes.
PCT/IB2006/051080 2006-04-09 2006-04-09 Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist Ceased WO2006079999A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (en) 2006-04-09 2006-04-09 Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (en) 2006-04-09 2006-04-09 Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist

Publications (2)

Publication Number Publication Date
WO2006079999A2 WO2006079999A2 (en) 2006-08-03
WO2006079999A3 true WO2006079999A3 (en) 2007-04-26

Family

ID=36740888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/051080 Ceased WO2006079999A2 (en) 2006-04-09 2006-04-09 Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist

Country Status (1)

Country Link
WO (1) WO2006079999A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin
EP4200021A1 (en) 2020-08-18 2023-06-28 Cybin IRL Limited Therapeutic phenethylamine compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARBER NURI B ET AL: "Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity", NEUROPSYCHOPHARMACOLOGY, vol. 18, no. 1, January 1998 (1998-01-01), pages 57 - 62, XP002396767, ISSN: 0893-133X *
WEST WILLIAM B ET AL: "Antagonism of a PCP drug discrimination by hallucinogens and related drugs", NEUROPSYCHOPHARMACOLOGY, vol. 22, no. 6, June 2000 (2000-06-01), pages 618 - 625, XP002396768, ISSN: 0893-133X *

Also Published As

Publication number Publication date
WO2006079999A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2008034041A3 (en) Therapeutic combinations
SI2044076T1 (en) Process for the preparation of asenapine and intermediate products used in said process.
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
WO2009063222A3 (en) Solid compositions
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2006044505A3 (en) Compounds for nonsense suppression, and methods for their use
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
CA2668320A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2007104780A3 (en) N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
JO2721B1 (en) Artemisinin Derivative Dimers, Their preparation and their therapeutic application
WO2007130822A3 (en) Mglur5 modulators iii
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
ZA201001085B (en) Indol-2-one derivatives disubstituted in the 3-position,preparation thereof and therapeutic use thereof
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
SG10201408374WA (en) Therapeutic Combinations Of Theobromine And An Antihistamine
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL198481A0 (en) Pyrrole derivatives, preparation use of the same in therapy
WO2011058373A3 (en) Drug combination with theobromine and its use in therapy
MX2009011294A (en) Drug combination and its use in the treatment of muscle loss.
WO2006079999A3 (en) Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2